BMO Capital lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $45 from $60 and keeps a Market Perform rating on the shares.

DTE Energy (NYSE:DTE – Get Free Report) had its price target boosted by investment analysts at BMO Capital Markets from ...

Ameren (NYSE:AEE – Get Free Report) had its target price lifted by research analysts at BMO Capital Markets from $100.00 to ...

At the meeting, Fed officials expressed concerns that tariffs and other Trump policies could slow progress on getting inflation back to their 2% target. The central bank is having a tough time gauging ...

Shares of Amazon (NASDAQ: AMZN) gained 0.52% on Wednesday, which was not enough to dig them out of a -1.58% loss over the ...

RBC Capital Markets has hired two senior consumer and retail bankers as it boosts its team covering mergers and acquisitions ...

BMO Capital analyst John McNulty maintained a Buy rating on Chemours Company (CC – Research Report) yesterday and set a price target of $27.00.

Q4 2024. Management View. CEO Jim Kessler highlighted a 13% increase in adjusted EBITDA for Q4, driven by disciplined execution and a ...

Net lease REIT W. P. Carey (NYSE:WPC) was upgraded at BMO Capital Markets on factors such as growth and incremental cost of capital.